IBC Life Sciences Release: TIDES Oligonucleotide and Peptide(R) Technology and Product Development

WESTBOROUGH, MA--(Marketwire - March 04, 2009) -

IBC’s TIDES Oligonucleotide and Peptide® Technology and Product Development will take place May 17-20, 2009 in Las Vegas, NV at the Red Rock Casino, Resort & Spa. This conference is a place for information on manufacturing technologies and drug development, as well as networking and business development in the field of oligonucleotide and peptide-based therapeutics and diagnostics.

The programming features new technologies, formulation and delivery regulatory updates, and courses on quality assurance, manufacturing RNA, bioanalytical techniques, managing analytical development and QC. In addition, attendees will hear case studies from Lilly, Avecia OligoMedicines, OncoGenex, Ipsen, Millennium and Pfizer along with technical and regulatory strategies from Merck, Bristol-Myers, U. of Washington, Regado, Alnylam and Isis.

Keynote Presentations include: Not Just a Message: Noncoding RNAs in Biology and Medicine Thomas R. Cech, Ph.D., Distinguished Professor, University of Colorado- Boulder; Nobel Laureate, 1989 (Chemistry) Human Genetics and Oligonucleotides: Essential Partners in Pharma’s Future Arthur M. Krieg, M.D., Chief Scientific Officer, Research Technology Center, Pfizer Inc Therapeutic Strategies Using RNA Interference John J. Rossi, Ph.D, Lidow Family Research Chair, Professor, Division of Molecular Biology; Dean, Graduate School of Biological Sciences; Beckman Research Institute of City of Hope Peptide Therapeutics: Trends in Global Clinical Development and Approval Janice M. Reichert, Ph.D., Senior Research Fellow, Tufts Center for the Study of Drug Development; Editor-in-Chief, mAbs, Landes Bioscience Taking Advantage of Peptide Aggregation Joel P. Schneider, Ph.D., Associate Professor, Department of Chemistry and Biochemistry, Department of Materials Science and Engineering, University of Delaware 

This forum focuses on development, manufacturing, business and regulatory challenges of oligonucleotide- and peptide-based therapeutics and diagnostics. It consists of 25 scientific sessions with over 80 presentations covering the current technology and market landscape to help attendees plan for future industry trends and meet people in the oligonucleotide and peptide drug development and manufacturing, as well as raw material and equipment supply, fields.

Registration for this event also gives attendees access to the co-located event “Applications of Nucleic Acids Technologies in Molecular Diagnostics.”

For more information and to register for this conference please visit, http://www.IBCLifeSciences.com/TIDES.

Digg this Bookmark with del.icio.us Add to Newsvine

Technorati: oligos peptides oligo peptide oligonucleotide RNA RNAi miRNA TIDES molecular diagnostics